Redefining and revisiting cost estimates of routine ART care in Zambia: an analysis of ten clinics.

AIDS HIV Zambia antiretroviral therapy costs and cost analysis low-resource setting

Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
02 2020
Historique:
received: 05 06 2019
revised: 11 10 2019
accepted: 20 11 2019
entrez: 18 2 2020
pubmed: 18 2 2020
medline: 5 11 2020
Statut: ppublish

Résumé

Accurate costing is key for programme planning and policy implementation. Since 2011, there have been major changes in eligibility criteria and treatment regimens with price reductions in ART drugs, programmatic changes resulting in clinical task-shifting and decentralization of ART delivery to peripheral health centres making existing evidence on ART care costs in Zambia out-of-date. As decision makers consider further changes in ART service delivery, it is important to understand the current drivers of costs for ART care. This study provides updates on costs of ART services for HIV-positive patients in Zambia. We evaluated costs, assessed from the health systems perspective and expressed in 2016 USD, based on an activity-based costing framework using both top-down and bottom-up methods with an assessment of process and capacity. We collected primary site-level costs and resource utilization data from government documents, patient chart reviews and time-and-motion studies conducted in 10 purposively selected ART clinics. The cost of providing ART varied considerably among the ten clinics. The average per-patient annual cost of ART service was $116.69 (range: $59.38 to $145.62) using a bottom-up method and $130.32 (range: $94.02 to $162.64) using a top-down method. ART drug costs were the main cost driver (67% to 7% of all costs) and are highly sensitive to the types of patient included in the analysis (long-term vs. all ART patients, including those recently initiated) and the data sources used (facility vs. patient level). Missing capacity costs made up 57% of the total difference between the top-down and bottom-up estimates. Variability in cost across the ten clinics was associated with operational characteristics. Real-world costs of current routine ART services in Zambia are considerably lower than previously reported estimates and sensitive to operational factors and methods used. We recommend collection and monitoring of resource use and capacity data to periodically update cost estimates.

Identifiants

pubmed: 32064766
doi: 10.1002/jia2.25431
pmc: PMC7025092
doi:

Substances chimiques

Anti-HIV Agents 0

Banques de données

ClinicalTrials.gov
['NCT02776254']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25431

Informations de copyright

© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

N Engl J Med. 2019 Jul 18;381(3):207-218
pubmed: 31314965
BMC Public Health. 2014 Mar 31;14:296
pubmed: 24684772
BMC Pediatr. 2016 Mar 15;16:41
pubmed: 26979974
Curr HIV/AIDS Rep. 2019 Aug;16(4):324-334
pubmed: 31230342
Hum Resour Health. 2011 Dec 19;9:30
pubmed: 22182366
Soc Sci Med. 2015 Apr;131:164-72
pubmed: 25779621
BMC Health Serv Res. 2019 Apr 24;19(1):244
pubmed: 31018846
Health Aff (Millwood). 2012 Jul;31(7):1553-60
pubmed: 22778345
PLoS One. 2014 Nov 12;9(11):e108304
pubmed: 25389777
J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):540-546
pubmed: 31021988
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21650
pubmed: 28770594
Health Policy Plan. 2002 Mar;17(1):112-8
pubmed: 11861593
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):22024
pubmed: 28770588
PLoS One. 2012;7(11):e48726
pubmed: 23144946

Auteurs

Austin Tucker (A)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Tannia Tembo (T)

Center for Infectious Disease Research (CIDRZ), Lusaka, Zambia.

Radhika P Tampi (RP)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Jacob Mutale (J)

Center for Infectious Disease Research (CIDRZ), Lusaka, Zambia.

Mpande Mukumba-Mwenechanya (M)

Center for Infectious Disease Research (CIDRZ), Lusaka, Zambia.

Anjali Sharma (A)

Center for Infectious Disease Research (CIDRZ), Lusaka, Zambia.

David W Dowdy (DW)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Carolyn B Moore (CB)

Center for Infectious Disease Research (CIDRZ), Lusaka, Zambia.
University of Alabama, Birmingham, AL, USA.

Elvin Geng (E)

Department of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Center for Dissemination and Implementation, Institute for Public Health at Washington University in St. Louis, St. Louis, MO, USA.

Charles B Holmes (CB)

Center for Infectious Disease Research (CIDRZ), Lusaka, Zambia.
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Georgetown University School of Medicine, Washington, DC, USA.

Izukanji Sikazwe (I)

Center for Infectious Disease Research (CIDRZ), Lusaka, Zambia.

Hojoon Sohn (H)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH